Document Detail


The Lescol Intervention Prevention Study (LIPS): start all patients on statins early after PCI.
MedLine Citation:
PMID:  12828227     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The Lescol Intervention Prevention Study (LIPS) was the first randomized trial to show a significant reduction in the risk of cardiac events in patients started on fluvastatin immediately after a successful percutaneous coronary intervention. The benefit was independent of baseline cholesterol levels. The results suggest that all patients should be discharged on lipid-lowering therapy after a percutaneous coronary intervention. Currently, this is seldom done.
Authors:
Adrian W Messerli; Herbert D Aronow; Dennis L Sprecher
Related Documents :
23478557 - Electrocardiographic findings suggestive of cardiomyopathy: what to look for and what t...
24106337 - Adipose-derived cell construct stabilizes heart function and increases microvascular pe...
25016707 - Serum levels of tenascin-c variants in congestive heart failure patients: comparative a...
24826297 - Coronary vasospasm while treating supraventricular tachycardia: is adenosine really to ...
21713377 - Coronary flow reserve varies depending upon the location within the artery it is assess...
8723597 - Acute hemodynamic deterioration during rapid atrial pacing in patients with hypertrophi...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Cleveland Clinic journal of medicine     Volume:  70     ISSN:  0891-1150     ISO Abbreviation:  Cleve Clin J Med     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-06-27     Completed Date:  2003-08-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8703441     Medline TA:  Cleve Clin J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  561-6     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary*
Coronary Artery Disease / drug therapy*
Double-Blind Method
Fatty Acids, Monounsaturated / therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Indoles / therapeutic use*
Prospective Studies
Chemical
Reg. No./Substance:
0/Fatty Acids, Monounsaturated; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Indoles; 93957-54-1/fluvastatin
Comments/Corrections
Comment In:
Cleve Clin J Med. 2003 Jun;70(6):502, 504-6   [PMID:  12828221 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Raising an isolated low HDL-C level: why, how, and when?
Next Document:  Predicting adolescent pedestrians' road-crossing intentions: an application and extension of the The...